We are live on ! Find out more
NNVC icon

NanoViricides

30 hedge funds and large institutions have $1.51M invested in NanoViricides in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more call options, than puts

Call options by funds: $312K | Put options by funds: $107K

0.23% more ownership

Funds ownership: 11.52%11.75% (+0.23%)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

3% less funds holding

Funds holding: 3130 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

34% less capital invested

Capital invested by funds: $2.3M → $1.51M (-$787K)

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
8
Reduced
8
Closed
6
Calls
$312K
Puts
$107K
Net Calls
+$205K
Net Calls Change
-$185K

NNVC Hedge Fund Activity: Q4 2022 in Review

30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NanoViricides (NNVC) for Q4 2022, worth a combined $1.51M — down 34% from $2.3M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of NNVC and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 8 added.

The largest buyer was Citadel Advisors, adding an estimated $81.6K. The largest seller was Morgan Stanley, cutting an estimated $36.9K.

  • 30 institutional investors held NanoViricides (NNVC) as of Q4 2022, down from 31 in Q3 2022.
  • Funds reported $1.51M of NanoViricides stock for Q4 2022, down 34% quarter-over-quarter.
  • 5 funds opened new NanoViricides positions in Q4 2022 and 6 closed out, a net change of -1 holder.
  • The largest NanoViricides buyer in Q4 2022 was Citadel Advisors, an estimated $81.6K added.
  • The largest NanoViricides seller in Q4 2022 was Morgan Stanley, an estimated $36.9K sold.

Based on aggregated 13F filings for Q4 2022.